Drug Interactions
Active Resources: 28
Online Training
-
7/13/2017
-
7/6/2017
-
5/1/2016
Clinical Reference Tools
-
5/3/2017 (reviewed: 5/3/2017)
-
4/28/2017
-
9/10/2015
Slide Sets
-
4/28/2017
-
4/28/2017
-
7/28/2016
-
9/29/2015
Webinars
-
1/12/2017
-
2/19/2013
Online and Self-Paced Learning
-
12/7/2016
-
11/16/2016
-
10/12/2016
Charts, Tables & Posters
-
7/1/2016
-
1/28/2015
-
1/1/2013
Image Library
-
4/6/2016
Toolkits
-
4/29/2015
Pocket Guides
-
4/1/2015
-
2/1/2014
-
11/30/2013
-
4/1/2013
Antiretroviral Guidelines
-
5/1/2014 (reviewed: 7/14/2016)
Manuals
-
4/30/2014
Coinfection Guidelines (Hep, TB, STIs)
-
3/27/2014 (reviewed: 10/31/2016)
-
6/1/2013
Archive Resources: 12
Slide Sets
-
4/11/2014
-
6/12/2012
-
6/1/2011
-
6/1/2011
-
3/1/2006
-
1/1/2006
Pocket Guides
-
7/1/2013
-
9/15/2009
-
1/1/2008
Curricula
-
11/1/2012
-
10/1/2008
Videos
-
11/9/2011
Articles: 14
-
Recap: 17th Ryan White HIV/AIDS Program Clinical Care Conference
Highlights from Laura W. Cheever, MD, ScM, HRSA HIV/AIDS Bureau Associate Administrator and Conference Co-Chair
The field of HIV/AIDS care and treatment continues to evolve rapidly. Groundbreaking developments in HIV research are regularly presented at international meetings and...
-
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy
Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...
-
START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV
The prevailing opinion among experts regarding the optimal CD4 T-cell count at which to start patients on antiretroviral therapy (ART) has shifted several times during the evolution of HIV treatment. These shifts reflect attempts to strike a balance between preventing HIV-associated illness and...
-
Adult and Adolescent Guidelines: Major Changes
The U.S. Department of Health and Human Services has released new treatment guidelines for adults and adolescents, and these contain some important changes. Key among these is a major shakeup in the "Recommended Regimen Options" for initial therapy.
Efavirenz/TDF/FTC (Atripla) has... -
Drug-Drug Interactions: Etravirine with Dolutegravir or Atazanavir
New data show that etravirine (ETR) substantially lowers plasma concentrations of dolutegravir (DTG) (DTG Cmin decreased 88%, AUC decreased 71%). This effect is lessened by coadministration of ritonavir-boosted PIs: the combination of ETR + DTG + darunavir/...
-
HIV Meds Updates: Fast Takes - ATV & Rilpivirine / Rifabutin
ATV pediatric powder formulationAn oral powder formulation of atazanavir has been approved by the FDA for use in infants and children older than 3 months and weighing 10 to <25 kg. It must administered with ritonavir, and used in combination with other antiretrovirals. For infants, it may be...
-
Drug Interactions: Integrase Inhibitors and Cations
Antacids, laxatives, mineral supplements, and other compounds that contain metal cations (eg, calcium, magnesium, aluminum, and iron) may decrease levels of integrase inhibitors if taken close in time to each other. Results of two studies help to assess the magnitude of this effect and assist in...
-
Clinically Significant Drug Interactions with Dolutegravir
Coauthor: Susa Coffey, MD; Medical Editor, AETC National Resource Center
Dolutegravir, the newly approved integrase inhibitor, has a number of important drug interactions with other medications and nutritional products. Listed below are highlights of some of the...
-
Updates to the Database of ARV Drug Interactions
The following table summarizes recent additions to the HIV InSite Database of Antiretroviral Drug Interactions. For a full description of the updates, including references to the studies from which the data were derived, go to the database, click on a specific drug name, and search for the...
-
Interactions with Hepatitis C Protease Inhibitors
Rilpivirine and BoceprevirBoceprevir (BOC) is a hepatitis C virus (HCV) NS3/4A protease inhibitor used in combination with pegylated interferon + ribavirin for the treatment of HCV. As BOC is an inhibitor of hepatic cytochrome (CYP) 3A4, and many protease inhibitors and NNRTIs affect or are...
-
Pitavastatin and Darunavir/Ritonavir
Coauthor: Susa Coffey, MD; Medical Editor, AETC National Resource Center
Treatment of dyslipidemia is often complicated by drug interactions between statins and antiretrovirals. Pitavastatin is one of the newer statins approved and is one of the few that is not...
-
More on Protease Inhibitors and Corticosteroids
It has been demonstrated previously that ritonavir significantly increases serum levels of inhaled and intranasal fluticasone and that coadministration with fluticasone should be avoided. Few studies have examined interactions between PIs and other corticosteroids. At the 19th...
-
More on Interactions between Darunavir and Pravastatin: To Use or Not to Use?
Recommendations for coadministration of pravastatin with darunavir have been based on a small PK study that showed substantial intersubject variability in the impact of interactions between the two drugs.[1] In that study, concurrent administration of pravastatin (40 mg, single...
-
ARV Interactions with HCV Serine Protease Inhibitors
Boceprevir and telaprevir, the hepatitis C virus (HCV) serine protease inhibitors, are likely to play important roles in the treatment of individuals with HIV/HCV coinfection, as well as in persons with HCV monoinfection. However, both boceprevir and telaprevir are inhibitors and substrates of...
| Day | Title |
|---|---|
|
5/11 |